http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018515621-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045 |
| filingDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018515621-A |
| titleOfInvention | Application of the composition in the preparation of a drug for the treatment of amyotrophic lateral sclerosis |
| abstract | The present invention relates to the preparation of a therapeutic agent for amyotrophic lateral sclerosis or related disorders of a composition comprising 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharmaceutically acceptable salt thereof and borneol. Regarding application, the drug is a drug that improves the onset time and survival time of amyotrophic lateral sclerosis, and a drug that improves memory dysfunction of amyotrophic lateral sclerosis. [Selection figure] None |
| priorityDate | 2015-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.